Kane Biotech Announces Third Quarter 2025 Financial Results

Core Insights - Kane Biotech Inc. reported its third quarter 2025 financial results, highlighting a significant decline in revenue compared to the same period in 2024, primarily due to the termination of an animal health manufacturing agreement and a US distribution agreement for its revyve product [7] Financial Performance - Total revenue for Q3 2025 was $8,499, a decrease from $1,282,698 in Q3 2024 [7] - Gross profit (loss) for Q3 2025 was $(5,128), compared to a gross profit of $558,754 in Q3 2024 [7] - Total operating expenses for Q3 2025 were $538,306, down from $1,170,064 in Q3 2024, attributed to staff reductions and lower compensation and business development costs [7] - Net loss for Q3 2025 was $(607,345), an improvement from a net loss of $(678,636) in Q3 2024 [7] - Cash as of September 30, 2025, was $939,062 [7] Clinical Developments - Kane Biotech is advancing its three-pillar strategy in wound care, with successful enrollment of 28 participants in its revyve Antimicrobial Wound Gel and Spray U.S. Case Series Studies, surpassing the target of 25 participants [2] - Clinical data presented at the Symposium on Advanced Wound Care (SAWC) Fall conference indicated promising results for revyve, with significant engagement from potential U.S. distributors [3] - New clinical data from The Diabetic Foot Conference (DFCon 2025) showed an average 97% area wound reduction in diabetic foot ulcers within four weeks and 100% wound closure in less than 12 weeks [4] - Pre-clinical data presented at the Southern Region Burn Conference demonstrated a six-log reduction in microbial load within 30 minutes using revyve, with sustained antibiofilm activity for at least seven days [5] Strategic Initiatives - The company plans to conduct further U.S.-based case series studies and report data at leading wound and burn care meetings [8] - Kane Biotech has submitted a 510(k) clearance application to the U.S. FDA for its revyve Antimicrobial Wound Cleanser and is working to establish a network of non-exclusive distributors and sales agents in the U.S. [9] - The Interim CEO emphasized the importance of the clinical data and distributor network in launching revyve in Canada and improving patient outcomes [10]